Merck & Co Inc (NYSE:MRK)

82.78
Delayed Data
As of Jun 14
 +0.43 / +0.52%
Today’s Change
59.80
Today|||52-Week Range
84.27
+8.34%
Year-to-Date
MRK Regular Dividend: MRK began trading ex-dividend on 06/14/19. A $0.55 dividend will be paid to shareholders of record as of 06/17/19.
Agilent Announces Receipt of FDA Approval for pharmDX Assay
Jun 14 / Zacks.comZAK - Paid Partner Content
6 Large-Cap Stocks Outperforming the Benchmark
Jun 12 / GuruFocus NewsGURU - Paid Partner Content
Dow 30 Stock Roundup: United Technologies-Raytheon Merger, Merck's Tilos Buyout
Jun 14 / Zacks.comZAK - Paid Partner Content
Merck's Keytruda Wins FDA Nod for First-Line Head/Neck Cancer
Jun 12 / Zacks.comZAK - Paid Partner Content
Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
Jun 13 / Zacks.comZAK - Paid Partner Content
Lilly Announces Tradjenta Cardiovascular Outcome Study Data
Jun 11 / Zacks.comZAK - Paid Partner Content
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock
Jun 13 / Zacks.comZAK - Paid Partner Content
Merck (MRK) to Buy Private Biotech Tilos for Up to $773M
Jun 11 / Zacks.comZAK - Paid Partner Content
IBM, KPMG, Merck and Walmart to collaborate as part of FDA's program to evaluate the ...
Jun 13 / PR NewswirePRN - Paid Partner Content
Merck (MRK) Gains But Lags Market: What You Should Know
Jun 10 / Zacks.comZAK - Paid Partner Content

Today’s Trading

Previous close82.35
Today’s open82.71
Day’s range82.46 - 83.37
Volume7,623,999
Average volume (3 months)10,107,697
Market cap$213.1B
Data as of 4:00pm ET, 06/14/2019

Growth & Valuation

Earnings growth (last year)+165.32%
Earnings growth (this year)+9.33%
Earnings growth (next 5 years)+8.45%
Revenue growth (last year)+6.17%
P/E ratio26.1
Price/Sales4.82
Price/Book8.04

Competitors

 Today’s
change
Today’s
% change
NVSNovartis-0.07-0.08%
PFEPfizer+0.26+0.61%
ABTAbbott Laboratories-0.07-0.09%
ABBVAbbVie-0.26-0.33%
Data as of 4:04pm ET, 06/14/2019

Financials

Next reporting dateJuly 30, 2019
EPS forecast (this quarter)$1.15
Annual revenue (last year)$42.4B
Annual profit (last year)$6.2B
Net profit margin14.65%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman, President &
Chief Executive Officer
Kenneth C. Frazier
CFO &
Executive Vice President-Global Services
Robert M. Davis
Corporate headquarters
Kenilworth, New Jersey

Forecasts